EC Number   |
Inhibitors |
Structure |
|---|
   3.4.22.66 | (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid |
- |
   |
| 3.4.22.66 | 1,6-di(propan-2-yl)-N-(4-[[4-(prop-2-en-1-yl)-5-sulfanylidene-4,5-dihydro-1H-1,2,4-triazol-3-yl]methyl]-1,3-thiazol-2-yl)-1H-pyrazolo[3,4-b]pyridine-4-carboxamide |
compound is predicted to bind to feline calicivirus proteases in a mode similar to that of the authentic substrate, and has the ability to inhibit viral protease activity in vitro and in the cells, and to suppress viral replication in FCV-infected cells. The authentic substrate and anti-FCV compound share a highly conserved binding site |
|
| 3.4.22.66 | 2-mercaptoethanol |
20% inhibited by 0.01 mM, 40% inhibited by 5 mM |
|
| 3.4.22.66 | 4-(2-aminoethyl)-benzene-sulfonyl fluoride |
irreversible inhibition, soluble stable nontoxic alternative to phenylmethylsulfonyl fluoride |
|
| 3.4.22.66 | benzyl ((3S,6S,9S,Z)-6-(cyclohexylmethyl)-9-formyl-4,7,12-trioxo-11H-5,8,13-triaza-1(4,1)-triazolacyclohexadecaphane-3-yl)carbamate |
- |
|
| 3.4.22.66 | benzyl ((3S,6S,9S,Z)-9-formyl-6-isobutyl-4,7,12-trioxo-11H-5,8,13-triaza-1(4,1)-triazolacyclohexadecaphane-3-yl)carbamate |
- |
|
| 3.4.22.66 | benzyl ((8S,11S,14S,Z)-11-(cyclohexylmethyl)-8-formyl-5,10,13-trioxo-11H-4,9,12-triaza-1(1,4)-triazolacyclopentadecaphane-14-yl)carbamate |
- |
|
| 3.4.22.66 | benzyl [(2S)-1-[[(2S)-3-methyl-1-oxo-1-([(2S)-1-oxo-3-[(1S)-2-oxocyclopentyl]propan-2-yl]amino)butan-2-yl]amino]-3-(naphthalen-1-yl)-1-oxopropan-2-yl]carbamate |
tripeptidyl compound, potent antiviral activities against both feline coronavirus strain WSU-79-1146 and feline calicivirus strain Urbana. Treatment of coronavirus-infected mice with the compound at 100 mg/kg results in a significant reduction in liver virus titers |
|
| 3.4.22.66 | Hg2+ |
5 mM completely inhibits |
|
| 3.4.22.66 | K+ |
inhibited by 100 mM |
|
